Treatment of APL has dramatically improved with the introduction of targeted therapies. The cornerstone of APL treatment is the use of all-trans retinoic acid (ATRA) in combination with arsenic trioxide (ATO). ATRA and ATO work synergistically to degrade the PML-RARA fusion protein and promote the differentiation of promyelocytes into mature granulocytes. This combination has shown high rates of complete remission and long-term survival.
